High-Flow Nasal Oxygen-Assisted Deep Extubation Versus Awake Extubation in Morbidly Obese Patients
HFNO-Assisted 'No-Touch' Deep Extubation Versus Conventional Awake Extubation in Morbidly Obese Patients Undergoing Elective Laparoscopic Surgery: A Prospective Randomized Controlled Trial
This prospective, randomized controlled trial aims to compare two methods of tracheal extubation after general anesthesia in adults with morbid obesity undergoing elective laparoscopic surgery.
A total of 120 patients will be randomly assigned to one of two groups. In the first group, the breathing tube will be removed while the patient remains deeply anesthetized, followed immediately by heated and humidified high-flow nasal oxygen (HFNO). Patients will then be allowed to awaken without unnecessary stimulation. In the second group, the breathing tube will be removed after the patient is fully awake, followed by conventional oxygen therapy through a face mask.
The primary objective is to determine whether HFNO-assisted deep extubation reduces the incidence of coughing during the first 15 minutes after extubation compared with conventional awake extubation.
The study will also assess respiratory complications, the need for airway interventions, hemodynamic changes, recovery times, and adverse events associated with the two extubation approaches.
The findings may help inform airway management strategies during recovery from general anesthesia in patients with morbid obesity.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ahmed Maged Nadar, M. B. B. Ch
- Phone Number: 01019510974
- Email: Ahmed.magednadar@yahoo.com
Study Contact Backup
- Name: Mina Mahrous Sobhy, M.D
- Phone Number: 01025273637
- Email: mms12@fayoum.edu.eg
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients aged 18-60 years. • BMI ≥ 40 kg/m² (morbidly obese). • American Society of Anesthesiologists (ASA) physical status classification II-III.
Patients scheduled for elective laparoscopic surgery .
• Mallampati score I or II (anticipated non-difficult airway).
Exclusion Criteria:
- Patients with known or anticipated difficult airway (Mallampati III-IV, previous history of difficult intubation, limited mouth opening, or cervical spine immobility).
Patients with severe obstructive sleep apnea (OSA) on home CPAP/BiPAP therapy who cannot tolerate nasal cannula delivery systems.
• Active gastroesophageal reflux disease (GERD) with aspiration risk.
• Patients with significant cardiovascular disease (NYHA class III-IV heart failure, unstable angina, or recent myocardial infarction within 6 months).
• Patients with severe pulmonary disease (FEV₁ < 50% predicted, chronic hypercapnia, or oxygen-dependent respiratory failure).
• Emergency surgical procedures.
• Patients with nasal obstruction, facial deformity, or conditions precluding HFNO delivery.
• Pregnant patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group D (Deep Extubation + HFNO Group)
Patients allocated to this group will undergo tracheal extubation while deeply anesthetized, after confirmation of adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Immediately after extubation, heated and humidified high-flow nasal oxygen (HFNO) will be administered at an initial flow rate of 40 L/min, adjustable up to 60 L/min as clinically indicated. Oxygen concentration will be titrated to maintain SpO₂ ≥92%. HFNO will be continued for 60 minutes in the post-anesthesia care unit (PACU). |
At the end of surgery, following adequate recovery from neuromuscular blockade (train-of-four ratio ≥0.9) and confirmation of adequate spontaneous ventilation, the endotracheal tube will be removed while the patient remains deeply anesthetized (end-tidal sevoflurane concentration ≥1.0 age-adjusted MAC). Immediately after extubation, heated and humidified high-flow nasal oxygen (HFNO) will be administered through nasal cannulae at an initial flow rate of 40 L/min, which may be increased to 60 L/min as clinically indicated. The initial FiO₂ will be 1.0 and subsequently titrated to maintain SpO₂ ≥92%. HFNO will continue for 60 minutes in the post-anesthesia care unit. Unnecessary stimulation during emergence will be avoided. |
|
Active Comparator: Group A (Awake Extubation Group)
Patients allocated to this group will undergo conventional awake tracheal extubation after discontinuation of general anesthesia, once they regain consciousness, respond to verbal commands, and meet standard extubation criteria, including adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Following extubation, supplemental oxygen will be administered through a simple face mask at 8-10 L/min for 60 minutes in the post-anesthesia care unit (PACU). |
At the end of surgery, general anesthesia will be discontinued, and tracheal extubation will be performed after the patient regains consciousness, responds to verbal commands, and fulfills standard extubation criteria, including adequate spontaneous ventilation and neuromuscular recovery (train-of-four ratio ≥0.9). Following extubation, supplemental oxygen will be administered via a simple face mask at 8-10 L/min for 60 minutes in the post-anesthesia care unit. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Coughing During Extubation and Early Emergence
Time Frame: During tracheal extubation and up to 15 minutes post-extubation
|
The proportion of patients experiencing at least one episode of coughing during tracheal extubation or within the first 15 minutes after extubation. Coughing will be recorded as a binary outcome (yes/no) for each participant, and the incidence will be compared between the two study groups. |
During tracheal extubation and up to 15 minutes post-extubation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severity of Coughing During Extubation and Early Emergence
Time Frame: During tracheal extubation and up to 15 minutes post-extubation
|
Cough severity will be assessed using the Modified Minogue Cough Scale, a four-grade ordinal scale: Grade 1, no coughing; Grade 2, mild coughing; Grade 3, moderate coughing; and Grade 4, severe coughing. Cough severity will be assessed during tracheal extubation and throughout the first 15 minutes after extubation. |
During tracheal extubation and up to 15 minutes post-extubation
|
|
Incidence of Laryngospasm
Time Frame: During emergence and up to 60 minutes after tracheal extubation
|
The proportion of participants who experience laryngospasm during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Laryngospasm will be recorded as present or absent (yes/no), and any episode will be classified as partial or complete. |
During emergence and up to 60 minutes after tracheal extubation
|
|
Incidence of Breath-Holding or Apnea
Time Frame: During emergence and up to 60 minutes after tracheal extubation
|
The proportion of participants experiencing at least one episode of breath-holding or apnea during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Events will be recorded as present or absent (yes/no), with the type of respiratory event documented when applicable. |
During emergence and up to 60 minutes after tracheal extubation
|
|
Heart Rate During Emergence and Early Postoperative Recovery
Time Frame: At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
Heart rate (HR), measured in beats per minute (bpm), will be recorded at pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation. Heart rate measurements at the predefined time points will be compared between the two study groups. |
At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
|
Mean Arterial Pressure During Emergence and Early Postoperative Recovery
Time Frame: At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
Mean arterial pressure (MAP), measured in millimeters of mercury (mmHg), will be recorded at pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation. Mean arterial pressure measurements at the predefined time points will be compared between the two study groups. |
At pre-induction baseline, immediately after tracheal extubation, and at 5, 10, 15, 30, and 60 minutes post-extubation.
|
|
Time From Extubation to Full Orientation
Time Frame: From tracheal extubation until full orientation during emergence
|
From tracheal extubation until achievement of full orientation, assessed for up to 60 minutes after extubation. |
From tracheal extubation until full orientation during emergence
|
|
Length of Stay in the Post-Anesthesia Care Unit
Time Frame: From PACU admission to PACU discharge
|
From admission to the post-anesthesia care unit (PACU) until PACU discharge, assessed for up to 4 hours after admission. |
From PACU admission to PACU discharge
|
|
Incidence of Bronchospasm
Time Frame: During emergence and up to 60 minutes after tracheal extubation
|
The proportion of participants experiencing at least one clinically diagnosed episode of bronchospasm during emergence from general anesthesia or within the first 60 minutes after tracheal extubation. Bronchospasm will be recorded as present or absent (yes/no). |
During emergence and up to 60 minutes after tracheal extubation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mohamed Ahmed Hamed Ismail, MD, Fayoum University
- Study Director: Abeer Shaaban Joda Morsi, MD, Fayoum University
Publications and helpful links
General Publications
- 2. Waheed Z, Amatul-Hadi F, Kooner A, Bhatti J, Afzal M, Ahmed R, et al. General anesthetic care of obese patients undergoing surgery: a review of current anesthetic considerations and recent advances. Cureus. 2023;15(7):e41565. 3. Pelosi P, Gregoretti C. Perioperative management of obese patients. Best Practice & Research: Clinical Anaesthesiology. 2010;24(2):211-225. 4. Rosén J, Frykholm P, Fors D. Effect of high-flow nasal oxygen on postoperative oxygenation in obese patients: a randomized controlled trial. Health Science Reports. 2022;5(3):e616. 5. Singh PA, Thong SY, Sivasankar R. Airway management in patients suffering from morbid obesity. Saudi Journal of Anaesthesia. 2022;16(3):314-321. 6. Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. British Journal of Anaesthesia. 2000;85(1):91-108. 7. Smith HC, Kinsella SM, Sellers WFS. A comparison of deep versus awake tracheal extubation in adults: a randomized controlled trial. Regional Anesthesia & Pain Medicine. 2024. doi:10.1136/rapm-2024-105362. 8. Abdelmalak BB, Maheshwari A, Mascha EJ. Evaluation of "no touch" extubation technique on airway-related complications during emergence from general anesthesia. Egyptian Journal of Anaesthesia. 2012;28(2):135-141. 9. Wang YK, Li X, Wei SY, Lv X. The effect of high-flow nasal cannula oxygen therapy on preventing hypoxemia during deep sedation extubation after laparoscopic surgery: a prospective randomized controlled trial. BMC Anesthesiology. 2026. doi:10.1186/s12871-026-03735-w. 10. Petkar S, Wanjari D, Priya V. A comprehensive review on high-flow nasal cannula oxygen therapy in critical care: evidence-based insights and future directions. Cureus. 2024;16(8):e66264. 11. Ferrando C, Puig J, Serralta F, Jimenez V, Gutierrez A, García M, et al. High-flow nasal cannula oxygenation reduces postoperative hypoxemia in morbidly obese patients: a randomized controlled trial. Minerva Anestesiologica. 2019;85(10):1062-1070.
- Hardt K, Wappler F. Anesthesia for Morbidly Obese Patients. Dtsch Arztebl Int. 2023 Nov 17;120(46):779-785. doi: 10.3238/arztebl.m2023.0216.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- M963
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
There is currently no plan to share individual participant data with external researchers. Study findings will be disseminated through scientific publications and presentations.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.